Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

  • Quanterix Serum Nf-L Assay Powers Key Trial and Study Results Presented at ECTRIMS 2019
    on September 16, 2019 at 10:21 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa technology and Nf-L assays were used in many of the groundbreaking research and treatment developments presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prior to the beginning of the conference, Quanterix announced that presentations leveraging Simoa increased by 40 percent from the 2018 ECTRIMS event, to a total of 49 references. The widespread adoption of Quanterix’ technology demonstrates the value it brings to advancing disease diagnosis and monitoring for Multiple Sclerosis.

  • Quanterix Simoa Technology Powers Multiple Sclerosis Research with More Than 50 Presentations at ECTRIMS 2019
    on September 11, 2019 at 12:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology has been referenced in more than 50 new research studies to be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), from Sept. 11-13, 2019 in Stockholm, Sweden. The number of presentations leveraging Simoa increased by over 40 percent since last year’s event, demonstrating widespread adoption of Quanterix’ technology by leading researchers dedicated to advancing disease diagnosis and monitoring for Multiple Sclerosis.

  • Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
    on August 13, 2019 at 8:21 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan Securities LLC and SVB Leerink LLC acted as joint book-running managers for the offering. Canaccord Genuity LLC acted as co-manager for the offering.

  • Quanterix Prices Public Offering of Common Stock
    on August 9, 2019 at 11:45 am

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share. All of the shares in the offering will be sold by Quanterix. Quanterix has also granted the underwriters a 30-day option to purchase up to an additional 356,435 shares of common stock on the same terms and conditions.

  • Quanterix Announces Proposed Public Offering of Common Stock
    on August 7, 2019 at 8:23 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In connection with the offering, Quanterix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price. All of the shares in the offering will be sold by Quanterix.

  • Quanterix Corporation (QTRX) Q2 2019 Earnings Call Transcript
    on August 7, 2019 at 12:25 pm

    QTRX earnings call for the period ending June 30, 2019.

  • Quanterix Corporation Releases Operating Results for Second Quarter 2019
    on August 6, 2019 at 12:30 pm

    $13.5M revenues, 57% Q2 YOY revenue growth and 520 bps of gross margin increas

  • Quanterix Announces Kevin Hrusovsky, Chairman and Chief Executive Officer, and Founder of Powering Precision Health, as EY Entrepreneur Of The Year® 2019 Award Winner in New England
    on June 28, 2019 at 4:15 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been recognized with the Entrepreneur Of The Year® 2019 Award in the New England region by EY. The award acknowledges Hrusovsky’s achievements in healthcare technology innovation, Quanterix’ outstanding financial performance, and his personal commitment to improving precision health. “We are honored to be recognized by EY,” said Hrusovsky.

  • Mass. diagnostics firms sign M&A deals worth $500M
    on June 27, 2019 at 2:43 pm

    Two local diagnostics firms, one of which is working in the increasingly competitive field of cancer testing, closed acquisition deals this week worth around $500 million.

  • Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier
    on June 26, 2019 at 8:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications.

4 days ago

Quanterix

Thrilled to have been at #ECTRIMS2019! Were you there? What was one key takeaway? Ours will be coming soon!This year's ECTRIMS Meeting was an absolute blast! Excellent Scientific Programme, a very impressive Industrial Exhibition as well as the best participants we could imagine. Thanks for coming and contributing to #ECTRIMS2019! ... See MoreSee Less

View on Facebook

1 years ago

Quanterix

On Memorial Day we must keep in mind the importance of continued research to improve brain health. Early detection of traumatic brain injuries can significantly improve the way we treat the condition and provide more effective options for soldiers and veterans. ... See MoreSee Less

View on Facebook

#Multiplesclerosis may have a long prodromal phase lasting several years before the first symptoms. https://t.co/lDjf8bxSR9 #ECTRIMS2019

Bjornek:Serum neurofilament light #sNfL chain levels in military personnel who developed #MS were elevated for years prior to first symptoms. Level rises more abruptly with first attack. #ECTRIMS2019

Today’s the last day to visit us at #ECTRIMS2019 booth A42! Stop by to hear more about the work we’re doing to disrupt #MS research and learn about the #biomarker technology powering more than 50 studies presented at this year’s show. https://t.co/QYsJnCvkMO

Interesting development out of this year’s #ECTRIMS2019 with a possible link between adolescent #concussions and development of #MS. With more research into critical indicators like NfL, we can detect and monitor the earliest stages of when these risks become diagnosable.

sal napoli md@napolineuro

Can concussion in adolescence increase risk in MS? We will need to study to assess if this is a potential risk factor? Secondary epitope spreading? #ECTRIMS2019

Could we see #MS in blood pre-symptomatically and use simple blood tests to monitor its progression? Researchers are using Simoa to find out. Learn more about this research at #ECTRIMS2019 booth A42. https://t.co/Lm2PsysEBH

Hey #ECTRIMS2019 attendees! Join us from 5-8 pm as we welcome Drs. Jens Kuhle & David Leppert from @UniSpitalBasel to discuss their groundbreaking @JAMANeuro study demonstrating the importance of #NfL as a disease progression marker in patients #MS https://t.co/62IbW5DYwR

Don’t forget to register for our 9/12 cocktail reception at #ECTRIMS2019 where we’ll share updates about our disruptive #MS research. We will also be hosting @UniSpitalBasel's Drs. Jens Kuhle & David Leppert to hear about their latest @JAMANeuro study! https://t.co/62IbW5DYwR

Simoa's impact on #MultipleSclerosis research grows stronger each year! Proud to once again be powering a record number of studies presented at @ectrimscongress' #ECTRIMS2019 this week. Visit booth A42 to learn more or click here: https://t.co/uStfps4loj #MS

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Quanterix Corporation

Building 1
900 Middlesex Turnpike
Billerica, MA 01821

+1 (617) 301-9400

www.quanterix.com

September 2019
S M T W T F S
« Aug    
1234567
891011121314
15161718192021
22232425262728
2930  

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account